At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Ruxolitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
In Brief
A Phase 2 clinical trial evaluating Long-term Follow-up, Quality-of-Life Assessment, and 1 other intervention for Myelofibrosis. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with myelofibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelofibrosis
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartSep 2016
Primary CompletionJan 2024
TodayJul 2026
First PostedMay 27, 2016
Enrollment StartSep 29, 2016
Primary CompletionJan 23, 2024
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 10.1 years ago
Interventions
Long-term Follow-upother
Undergo follow-up assessment
Quality-of-Life Assessmentother
Ancillary studies
Ruxolitinibdrug
Given PO